Contract research
It is a long path from the development of an active pharmaceutical ingredient in the lab to an effective drug – a process that takes several years. Campus companies are often involved in this process on behalf of the pharmaceutical and biotech industry or academic groups.
The company Experimental Pharmacology & Oncology Berlin-Buch (EPO) is a leader in preclinical cancer research in Germany. Worldwide, EPO offers customized and comprehensive service for the preclinical development of novel cancer drugs and is specialized in the development of individualized tumor models.
News innovation
Eckert & Ziegler and GlyTherix Sign Agreement for Lutetium-177 Supply
Eckert & Ziegler (ISIN DE0005659700, SDAX) and GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company specialising in developing antibody radiopharmaceuticals for solid tumors, today a...
more ...Eckert & Ziegler: Spin-off of Pentixapharm AG Registered with the Commercial Register
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) announces that the spin-off resolution approved at the Annual General Meeting on 26 June 2024 was entered in the commercial register of the Charlottenbu...
more ...OMEICOS Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial Disease
Interim data confirms OMT-28's strong safety profile in PMD patients, top-line data expected mid-2025
more ...Events Campus
16.10.2024, 17:00
Konzert-Abend in Buch mit Duo Cello Capricioso
Das Programm „Enthüllung einer Welt“ ist eine Hommage an das Violoncello und seine vielfältigen Ausdrucksmöglichkeiten.
more ...
